Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Protective Protein Drastically Reduced Following Brain Injury

By LabMedica International staff writers
Posted on 25 May 2011
The protein produced by the KCC2 gene acts to prevent damage to neurons following trauma to the brain caused by head injury, stroke, or neurodegenerative diseases such as Alzheimer's.

KCC2 is a member of the cation-chloride cotransporter gene family. More...
KCCs normally lower intracellular chloride concentrations below the electrochemical equilibrium potential and depending on the chemical concentration gradients of potassium and chloride, KCC2 can operate as a net efflux or influx pathway. KCC2 is expressed at high levels in neurons throughout the nervous system and immunofluorescence has shown that the protein was localized at inhibitory synapses of the spinal cord. Previous studies had shown that the level of KCC2 dropped drastically after brain injury.

Investigators at the Université de la Méditerranée (Marseille, France) used primary hippocampal neuronal cultures to study KCC2 function. In this system, they could block the action of KCC2 either by an RNA interference approach or by using a dominant negative mutant. KCC2 activity was restored by gene therapy that overexpressed the active form of the KCC2, while overexpression of its nonactive mutant Y1087D was used as a control.

Results published in the May 15, 2011, issue of the Journal of Physiology revealed that the experimental silencing of endogenous KCC2 reduced neuronal resistance to toxic insults. In contrast, the artificial gain of KCC2 induced by overexpression of KCC2 gene function in the same neurons protected them from death. Overexpression of the nonactive mutant Y1087D had no protective effect.

"The death of neurons in the brain can be triggered by an imbalance of oxygen – known as oxidative damage, or where cells are incorrectly instructed to die by a neurotransmitter – a process known as excitotoxicity, " said senior author Dr. Igor Medina, professor of medicine at the Université de la Méditerranée. "KCC2 protects against both. It is really encouraging that we have identified a means of potentially protecting the brain from these common conditions. The destiny of neurons in a damaged brain depends on a tiny equilibrium between prosurvival and prodeath signals. We wanted to know what KCC2 was signaling for – was it killing neurons or protecting them after an injury? Our study has found that KCC2 actually rescues the damaged cells."

"Neuroprotective agents that may stem from this research would benefit the victims of car crashes, stroke, and those suffering with epilepsy, Parkinson's, and Alzheimer's – it is a major focus for further studies," said Dr Medina.

Related Links:
Université de la Méditerranée




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.